Tevogen Bio Holdings Inc.

NasdaqGM:TVGN Stock Report

Market Cap: US$27.0m

Tevogen Bio Holdings Management

Management criteria checks 3/4

Tevogen Bio Holdings' CEO is Ryan Saadi, appointed in Feb 2024, has a tenure of 2.17 years. total yearly compensation is $10.42M, comprised of 4.8% salary and 95.2% bonuses, including company stock and options. directly owns 59.78% of the company’s shares, worth $16.16M. The average tenure of the management team and the board of directors is 2.2 years and 3.7 years respectively.

Key information

Ryan Saadi

Chief executive officer

US$10.4m

Total compensation

CEO salary percentage4.81%
CEO tenure2.2yrs
CEO ownership59.8%
Management average tenure2.2yrs
Board average tenure3.7yrs

Recent management updates

Recent updates

Tevogen Bio Holdings: Initiating Sell Rating Based On Pipeline Uncertainty And Cash Constraints

Apr 11

Tevogen Bio Claims $10 Billion IP Potential But Hinges On Monetization

Dec 16

CEO Compensation Analysis

How has Ryan Saadi's remuneration changed compared to Tevogen Bio Holdings's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2025US$10mUS$501k

-US$27m

Sep 30 2025n/an/a

-US$31m

Jun 30 2025n/an/a

-US$31m

Mar 31 2025n/an/a

-US$31m

Dec 31 2024US$88mUS$501k

-US$10m

Sep 30 2024n/an/a

-US$4m

Jun 30 2024n/an/a

-US$2m

Mar 31 2024n/an/a

-US$19m

Dec 31 2023US$501kUS$501k

-US$60m

Sep 30 2023n/an/a

-US$63m

Jun 30 2023n/an/a

-US$64m

Mar 31 2023n/an/a

-US$47m

Dec 31 2022US$454kUS$453k

-US$22m

Compensation vs Market: Ryan's total compensation ($USD10.42M) is above average for companies of similar size in the US market ($USD618.13K).

Compensation vs Earnings: Ryan's compensation has been consistent with company performance over the past year.

CEO

Ryan Saadi (60 yo)

2.2yrs
Tenure
US$10,421,000
Compensation

Dr. Ryan Saadi, M.D., M.P.H., has been Chief Executive Officer and Chairperson of Tevogen Bio Holdings Inc. since February 14, 2024. He served as Chief Executive Officer and Chairperson of Tevogen Bio begi...

Leadership Team

NamePositionTenureCompensationOwnership
Ryan Saadi
Co-Founder2.2yrsUS$10.42m59.78%
$ 16.2m
Kirti Desai
Chief Financial Officer2.2yrsUS$1.23m4.87%
$ 1.3m
Neal Flomenberg
Chief Scientific Officer and Global R&D Lead3.8yrsUS$722.00k1.7%
$ 458.5k
Stephen Chen
Chief Technical Officer4yrsno datano data
Mittul Mehta
Chief Information Officer & Head of Tevogen.ai2.4yrsno datano data
Tapan Shah
Head of Investor Relations & Corporate Development2yrsno datano data
Sadiq Khan
Chief Commercial Officer & Interim Head of Tevogen Generics2.2yrsno data0.56%
$ 151.8k
David Banko
Global Head of Government Affairs & Patient Access1.1yrsno datano data
2.2yrs
Average Tenure
65.5yo
Average Age

Experienced Management: TVGN's management team is considered experienced (2.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Ryan Saadi
Co-Founder2.2yrsUS$10.42m59.78%
$ 16.2m
Manmohan Patel
Member of Advisory Board4.3yrsno data6.43%
$ 1.7m
Bruce Cooper
Member of Advisory Board4.3yrsno datano data
Victor Sordillo
Independent Director2.8yrsUS$478.08k0.19%
$ 50.5k
Keow Lin Goh
Independent Director3.7yrsUS$239.04k0.12%
$ 33.0k
Jeffrey Feike
Independent Director2.2yrsUS$239.04k0.31%
$ 83.3k
Susan Podlogar
Independent Director3.7yrsUS$239.04k0.12%
$ 33.0k
Curtis Patton
Independent Director2.2yrsUS$239.04k0.49%
$ 133.6k
Sten Vermund
Member of Advisory Board4.3yrsno datano data
Kendell Sprott
Member of Advisory Board3.8yrsno datano data
Afshin Beheshti
Member of Advisory Board2.3yrsno datano data
3.7yrs
Average Tenure
72yo
Average Age

Experienced Board: TVGN's board of directors are considered experienced (3.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/04/29 07:18
End of Day Share Price 2026/04/29 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Tevogen Bio Holdings Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason KolbertD. Boral Capital LLC.